Cargando…

Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative

Among the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosch, Francesc, Navarro, Blanca, Crespo, Marta, Alcoceba, Miguel, Sánchez, Julio Bravo, Tazón, Barbara, Serrano, Alicia, Álvarez, María García, Serrano, Lydia González, Alonso-Torres, Pablo, Villanueva, Miguel, Loriente, Cristina, Abrisqueta, Pau, Peiró, Manel, García-Marco, José Antonio, González, Marcos, Terol, María José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914181/ https://www.ncbi.nlm.nih.gov/pubmed/33409623 http://dx.doi.org/10.1007/s00277-020-04331-9

Ejemplares similares

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
por: Puiggros, Anna, et al.
Publicado: (2017)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
por: Abrisqueta, Pau, et al.
Publicado: (2022)

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
por: Blanco, Gonzalo, et al.
Publicado: (2016)

The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers
por: Garrido-Navas, M. Carmen, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis
por: García-Álvarez, María, et al.
Publicado: (2017)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
por: Quijada‐Álamo, Miguel, et al.
Publicado: (2021)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
por: Jiménez, Isabel, et al.
Publicado: (2021)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
por: Soto, José Luis, et al.
Publicado: (2005)

The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome
por: Rodríguez-Caballero, Arancha, et al.
Publicado: (2021)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2
por: Fagiani, Francesca, et al.
Publicado: (2020)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

The Brazilian TP53 mutation (R337H) and sarcomas
por: Volc, Sahlua Miguel, et al.
Publicado: (2020)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

TP53 Abnormalities and MMR Preservation in 5 Cases of Proliferating Trichilemmal Tumours
por: Martín-Sanz, Raquel, et al.
Publicado: (2021)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas
por: García-Álvarez, María, et al.
Publicado: (2019)

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans
por: Xia, Yi, et al.
Publicado: (2014)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

Mutational status of K- ras and TP53 genes in primary sarcomas of the heart
por: Garcia, J M, et al.
Publicado: (2000)

DOR/Tp53inp2 and Tp53inp1 Constitute a Metazoan Gene Family Encoding Dual Regulators of Autophagy and Transcription
por: Sancho, Ana, et al.
Publicado: (2012)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

The Role of TP53 in Adaptation and Evolution
por: Voskarides, Konstantinos, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_998229j4smas2ocp5glp2d7ddc